Local Coverage Determination (LCD): MolDX: Genetic Testing for CYP2C19, CYP2D6, CYP2C9, and VKORC1 (L36398)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	State(s)
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05101 - MAC A	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05102 - MAC B	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05201 - MAC A	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05202 - MAC B	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05301 - MAC A	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05302 - MAC B	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05401 - MAC A	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05402 - MAC B	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05901 - MAC A	J - 05	Alaska Alabama Arkansas Arizona Connecticut Florida Georgia Iowa Idaho Illinois Indiana Kansas Kentucky Louisiana Massachusetts Maine Michigan Minnesota Missouri - Entire State Mississippi Montana North Carolina North Dakota Nebraska New Hampshire New Jersey Ohio Oregon Rhode Island South Carolina South Dakota Tennessee

Contractor Name	Contract Type	Contract Number	Jurisdiction	State(s)
				Utah Virginia Virgin Islands Vermont Washington Wisconsin West Virginia Wyoming
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08101 - MAC A	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08102 - MAC B	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08201 - MAC A	J - 08	Michigan
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08202 - MAC B	J - 08	Michigan

Back to Top

LCD Information

Document Information

LCD ID
L36398

LCD Title
MolDX: Genetic Testing for CYP2C19, CYP2D6, CYP2C9, and VKORC1

Proposed LCD in Comment Period
N/A

Source Proposed LCD
N/A

Original Effective Date
For services performed on or after 04/16/2016

Revision Effective Date
For services performed on or after 10/01/2017

Revision Ending Date
N/A

Retirement Date
N/A

Notice Period Start Date
03/01/2016

Notice Period End Date
04/15/2016

CMS National Coverage Policy
CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim which lack the necessary information to process the claim.

Title XVIII of the Social Security Act, §1862(a)(1)(D) items and services related to research and experimentation.

42CFR 410.32(a) Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

42CFR 411.15(k)(1) Particular services excluded from coverage.

CMS Publication 100-3, *Medicare National Coverage Determinations (NCD) Manual*, Chapter 1, §90.1 Pharmacogeneomic Testing for Warfarin Response.

CMS Publication 100-08, *Medicare Program Integrity Manual*, Chapter 3-Verifying Potential Errors and Taking Corrective Actions, §3.4.1.3-Diagnosis Code Requirements.

Coverage Guidance
Coverage Indications, Limitations, and/or Medical Necessity

This policy limits CYP2C19 and CYP2D6 genetic testing to defined indications. All other testing for CYP2C19 and CYP2D6 is non-covered until definitive clinical utility is established to justify coverage.

I. **CYP2C19 Genotyping**
Background on CYP2C19 Testing
The CYP450 gene superfamily is composed of many isoenzymes that are involved in the metabolism of about 75% of commonly prescribed drugs. CYP2C19 metabolizes 15% of all currently used drugs, whereas CYP2D6 enzymes metabolize approximately 20-25%, and CYP2C9 metabolizes approximately 10%.

Genetic alterations or "polymorphisms" are common in these isoenzymes, with more than 30 polymorphisms identified in CYP2C19. These polymorphisms can lead to differences in individual drug response secondary to variation in metabolism.

CYP2C19 phenotypes include poor, intermediate, extensive and ultra-rapid metabolizers. The frequency of the various metabolizer phenotypes has been estimated as follows:

- 2-15% - poor metabolizers
- 18-45% - intermediate metabolizers
- 35-50% - extensive metabolizers
- 5-30% - ultra-rapid metabolizers

The genotypic rates vary by ethnicity. Approximately 2% of whites, 4% of blacks and 14% of Chinese are poor CYP2C19 metabolizers.

Pharmacogenetic testing has been proposed to predict individual response to a variety of CYP2C19-metabolized drugs including clopidogrel, proton pump inhibitors, and tricyclic antidepressants, among others. In certain scenarios, an individual patient may benefit from genetic testing in determining dosage and likely response to specific medications.

Clopidogrel bisulfate (Plavix) is a widely prescribed medication to/for:
- Prevent blood clots in patients with acute coronary syndrome (ACS);
- Other cardiovascular (CV) disease-related events;
- Undergoing percutaneous coronary intervention

Clopidogrel response varies significantly due to genetic and acquired factors including obesity, smoking and noncompliance. Patients with poor response to clopidogrel may experience recurrent CV event or thrombotic events while taking clopidogrel. They are at greater risk for major adverse CV events such as heart attack, stroke and death. These individuals are typically poor to intermediate metabolizers of clopidogrel due to the presence of the associated CYP2C19 polymorphisms. These individuals should be given an alternate treatment strategy (Plavix PI). As such, the clinical utility of CYP2C19 genotyping has been supported with net benefits on improving health outcomes for individuals with ACS who are undergoing percutaneous coronary interventions (PCI). There is insufficient evidence of clinical utility of CYP2C19 genotyping for individuals considering clopidogrel therapy for other indications, such as medical management of ACS without PCI, stroke, or peripheral artery disease.

With regards to CYP2C19 testing for antidepressant treatment, recent evidence has suggested genetic testing prior to initiating certain tricyclic antidepressants, namely amitriptyline, due to the effects of the genotype on drug efficacy and safety. Use of this information to determine dosing has been proposed to improve clinical outcomes and reduce the failure rate of initial treatment. However, the Clinical Pharmacogenetics Implementation Consortium did not have enough evidence to make a strong recommendation for dose modification based on genotype, and a moderate recommendation was given based on data outside of randomized trials. Additionally, even with genotype information, a suggestion is given to start patients on low dose, gradually increasing to avoid adverse side effects. Consequently, genotyping is not needed with this approach.

Proton pump inhibitors are used to treat several gastric acid-related conditions including duodenal ulcer, gastric ulcer and gastroesophageal reflux disease. Proton pump inhibitors can also be used to treat Helicobacter pylori. Several proton pump inhibitors are metabolized by CYP2C19. However, there is insufficient data to warrant CYP2C19 genotyping to determine health outcomes or adverse drug reactions in treatment with proton pump inhibitors.

With regards to Serotonin reuptake inhibitors, there is insufficient evidence to support CYP2C19 genotyping to determine medical management for the treatment of obsessive compulsive disorder at this time.

Covered Indications
In summary, genetic testing of the CYP2C19 gene is considered medically necessary for patients with ACS undergoing PCI who are initiating or reinitiating Clopidogrel (Plavix) therapy,

Non-covered Indications
Genetic testing for the CYP2C19 gene is considered investigational at this time for the following medications including but not limited to:
- Amitriptyline
- Clopidogrel for indications other than above
- Proton pump inhibitors
- Selective serotonin reuptake inhibitors
- Warfarin

II. **CYP2D6 Genotyping**

Background on *CYP2D6* Testing

Genetic alterations or "polymorphisms" are common in these isoenzymes, with more than 100 polymorphisms identified in *CYP2D6*. These polymorphisms can lead to differences in individual drug response secondary to variation in metabolism.

CYP2D6 phenotypes include poor, intermediate, extensive and ultra-rapid metabolizers. The frequency of the poor metabolizer phenotype varies by ethnicity with 7-10% in Caucasians, 1.9-7.3% in African-Americans, and ≤ 1% in most Asian populations studied. The extensive metabolizer phenotype, observed in 50% of Caucasians, is the most common in this population. Genetic variation, as well as drug-drug interactions, can influence the classification of *CYP2D6* metabolism into one of the above phenotypes. In addition, chronic dosing of a *CYP2D6* drug can inhibit its own metabolism over time as the concentration of the drug approaches a steady state.

Pharmacogenetic testing has been proposed to predict individual response to a variety of CYP2D6-metabolized drugs including tamoxifen, antidepressants, opioid analgesics, and tetrabenzine for chorea, among others. In certain scenarios, an individual patient may benefit from this genetic testing in determining dosage and likely response to specific medications.

Tamoxifen

Available evidence fails to support direct evidence of clinical utility for testing of CYP2D6 in treatment with tamoxifen. Tamoxifen metabolism and the causes for resistance are complex rather than the result of a single polymorphism.

Antidepressants

In regards to CYP2D6 testing for antidepressant treatment, there was insufficient evidence in the past to support testing to determine treatment. More recently, evidence has supported the use of genetic testing prior to initiating certain tricyclic antidepressants due to the effects of genotype on drug efficacy and safety. Use of this information to determine dosing can improve clinical outcomes and reduce the failure rate of initial treatment. However, there is insufficient evidence for CYP2D6 genotyping for individuals considering antipsychotic medications or other antidepressants with CYP2D6 as a metabolizing enzyme.

Codeine

In addition, the role of CYP2D6 genotyping has been evaluated for use in opioid analgesic drug therapy, specifically codeine analgesia. The efficacy and toxicity, including severe or life- threatening toxicity after normal doses of codeine has been linked to an individual's CYP2D6 genotype. However, genotyping would indicate avoidance of codeine due to risk of adverse events in only 1-2% of the populations, and there is considerable variation in the degree of severity of adverse events, with most not classified as serious. Furthermore, codeine is widely used without genotyping. At this time, there is insufficient evidence to support clinical utility of genotyping for management of codeine therapy.

Tetrabenazine for treatment of Huntington's disease

The dosing of tetrabenazine is based, in part, on CYP2D6 genotyping. However, a recent study suggests that the necessity to genotype may need to be reconsidered. The Xenazine® manufacture package insert indicates that poor metabolizers of CYP2D6 should not exceed a maximum does of 50 mg/day.

Drugs for Alzheimer's Disease

Galantamine is an antidementia drug used in the treatment of Alzheimer's disease. Studies have been performed that reveal the *CYP2D6* genotype significantly influences galantamine concentrations in blood. Still other studies have revealed that urinary assays for *CYP2D6* phenotype are technically feasible. At this time, the association between phenotype and drug responsiveness remains unknown. It has been suggested that confirmation studies in larger populations are necessary to establish evidence regarding individuals most likely to benefit from galantamine, including information on treatment efficacy and tolerability.

Donepezil (Aricept) is a drug used to treat an Alzheimer's disease. Some studies have reported an influence of the *CYP2D6* on the response to treatment with this drug. Other studies suggest that therapy based on *CYP2D6* genotype is unlikely to be beneficial for treating Alzheimer's disease patients in routine clinical practice. Additional studies are needed to determine the efficacy and utility of *CYP2D6* genotyping in those patients who are treated with donepezil.

Covered Indications

In summary, genetic testing of the CYP2D6 gene is considered medically necessary to guide medical treatment and/or dosing for individuals for whom initial therapy is planned with:

- Amitriptyline or nortriptyline for treatment of depressive disorders
- Tetrabenazine doses greater than 50 mg/day or re-initiation of therapy with doses greater than 50 mg/day.

Non-covered Indications There is insufficient evidence to demonstrate that genetic testing for the CYP2D6 gene improves clinical outcomes. Consequently, genetic testing for the CYP2D6 gene is considered investigational including but not limited to the following medications:

- Antidepressants other than those listed above
- Antipsychotics
- Codeine
- Donepezil
- Galantamine
- Tamoxifen

III. **CYP2C9 Genotyping**

Background on CYP2C9 Testing

CYP2C9 metabolizes approximately 10-15% of all currently used drugs. Genetic alternations or "polymorphisms" are common in these isoenzymes, with 57 polymorphisms identified in CYP2C9, which can lead to differences in individual drug response secondary to variation in metabolism. Pharmacogenetic testing has been proposed to predict individual response to a variety of CYP2C9-metabolized drugs including celecoxib, fluorbiprofen, fluvoxamine and warfarin, among others. In certain scenarios, an individual patient may benefit from this genetic testing in determining dosage and likely response to specific medications. However, there is insufficient evidence to support CYP2C9 genotyping to determine medical management and alter outcomes at this time.

Individuals with low enzyme activity for CYP2C9 substrates are at risk of adverse drug reactions. However, pharmacogenetic testing for individuals being treated with drugs, such as warfarin, may experience little or no benefit from testing. This is, in part, because the CYP2C9 genotype accounts for only part of the variability in drug sensitivity.

Warfarin

While there is extensive literature regarding warfarin and the CYP2C9 genotype, the clinical utility of such testing remains unproven at this time. In fact, pharmacogenetic testing for warfarin treatment has been recommended against by the American College of Medical Genetics and the American College of Chest Physicians. These guidelines suggest that genetic testing for warfarin metabolism is not medically necessary, and evidence of clinical utility remains to be proven. Obstacles for determining clinical utility have been reviewed with suggestions for researchers in this area.

Celecoxib

In addition, limited information is available regarding celecoxib metabolism in individuals with CYP2C9 polymorphisms. More trials are needed to determine clinical utility and appropriateness of pharmacogenetic testing in this population.

Covered Indications

Effective August 3, 2009, the Centers for Medicare & Medicaid Services (CMS) believes that the available evidence supports that coverage with evidence development (CED) under §1862(a)(1)(E) of the Social Security Act (the Act) is appropriate for pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness by any method, and is therefore covered only when provided to Medicare beneficiaries who are candidates for anticoagulation therapy with warfarin who:

- Have not been previously tested for CYP2C9 or VKORC1 alleles; and
- Have received fewer than five days of warfarin in the anticoagulation regimen for which the testing is ordered; and
- Are enrolled in a prospective, randomized, controlled clinical study when that study meets the following standards.

Non-covered Indications

All other coverage for genetic testing for the CYP2C9 gene is considered investigational at this time. There is currently no proven clinical utility related to any medication, including but not limited to:

- Celecoxib
- Fluorbiprofen
- Flovoxamine

IV. **VKORC1 Genotyping**

Background on VKORC1 Testing

The vitamin K epoxide reductase complex subunit 1, encoded by the gene VKORC1, is critical in the vitamin K pathway for coagulation. Warfarin therapy targets VKORC1 to reduce clotting risk.

Variation in response to warfarin therapy has been linked to genetic variations. Retrospective study of European-American patients undergoing long term warfarin therapy identified 5 major haplotypes that were most predictive of approximately 25% of variance in warfarin dose. These are classified into A: low dose haplotype and B: high dose haplotype. This was validated in two European-American populations. Average maintenance dose for A/A haplotypes was approximately 2.7 mg per day; 4.9 mg per day for A/B, and 6.2 mg per day for B/B ($p<0.001$).

Review by the American College of Medical Genetics (2008) confirmed the analytic validity of testing VKORC1 and confirmed that there is sufficient evidence to support association with final therapeutic dose of warfarin. However, safe warfarin dosing requires careful monitoring and there is insufficient evidence available to support routine VKORC1 genotyping for determination of final dosing. Further studies in prospective clinical trials are needed to determine clinical utility.

Clinical Pharmacogenetics Implementation Consortium guidelines recommend that pharmacogenetic algorithms be used to determine ideal dosing, and recommend including VKORC1 genotyping when available. However the evidence from randomized prospective trials is limited, and impact on clinical outcomes is not yet known, limiting the ability to recommend that genotyping be performed for initial warfarin prescribing.

Prospective study of 30 healthy subjects assessed for warfarin dosing with daily INR measurements determined that VKORC1 ($p=0.02$) variant carriers require lower cumulative doses of warfarin to achieve INR $\geq$ 2.0. Participants who carried variants in both CYP2C9 and VKORC1 required fewer days to achieve INR $\geq$ 2.0 that wild type subjects ($p=0.01$) resulting in an estimated genetic contribution to dose variability of 62%.

Meta-analysis of CYP2C9 and VKORC1 genotypes influence the risk of hemorrhagic complications in warfarin treated patients and increase the risk for over-coagulation and hemorrhagic complications with CYP2C9*3 carriers. No significant association was noted between VKORC1 genotypes and hemorrhagic complications.

Randomized controlled study assessing 109 adult patients and the influence of VKORC1 genotyping data on clinical outcomes of initial warfarin dosing was performed. Primary endpoints included time in therapeutic range over 90 days and number of anticoagulation visits. Hospitalizations, emergency visits, time to reach therapeutic dose, INR >4, hemorrhagic events, thrombotic events and mortality were secondary endpoints. No difference in the primary endpoints was noted between patients who received initial dosing by clinical and genotype information as compared to those whose initial dosing was determined by clinical information alone. No statistical difference was noted between either group in secondary events, however fewer of these events were noted among patients whose dosing included genotypic data.

V. **Covered Indications**

Effective August 3, 2009, the Centers for Medicare & Medicaid Services (CMS) believes that the available evidence supports that coverage with evidence development (CED) under §1862(a)(1)(E) of the Social Security Act (the Act) is appropriate for pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness by any method, and is therefore covered only when provided to Medicare beneficiaries who are candidates for anticoagulation therapy with warfarin who:

- *Have not been previously tested for CYP2C9 or VKORC1 alleles; and*
- *Have received fewer than five days of warfarin in the anticoagulation regimen for which the testing is ordered; and*
- *Are enrolled in a prospective, randomized, controlled clinical study when that study meets the standards as outlined in NCD 90.1 - Pharmacogenomic Testing to Predict Warfarin Responsiveness.*

VI. **Non-covered Indications**

Genetic testing for the VKORC1 gene is considered investigational at this time for all other medications.

Summary of Evidence

N/A

Analysis of Evidence
(Rationale for Determination)

N/A

Back to Top

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

CPT/HCPCS Codes

Group 1 Paragraph:

N/A

Group 1 Codes:

81225	CYP2C19 (CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 19) (EG, DRUG METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, *2, *3, *4, *8, *17)

Group 2 Paragraph:

N/A

Group 2 Codes:

81226	CYP2D6 (CYTOCHROME P450, FAMILY 2, SUBFAMILY D, POLYPEPTIDE 6) (EG, DRUG METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)

Group 3 Paragraph:

CPT codes CYP2C9 and VKORC1 are non-covered for all indications per this policy. However, CYP2C9 and VKORC1 can be covered in accordance with NCD 90.1 and should be reported with HCPCS code G9143 warfarin responsiveness testing.

Group 3 Codes:

81227 CYP2C9 (CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 9) (EG, DRUG METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, *2, *3, *5, *6)

81355 VKORC1 (VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1) (EG, WARFARIN METABOLISM), GENE ANALYSIS, COMMON VARIANT(S) (EG, -1639G>A, C.173+1000C>T)

Group 4 Paragraph:

CYP gene panels (testing for more than 1 CYP gene on same date of service) is a single unit of service (UOS=1). All CYP panels should be billed with 81479 and are non-covered.

Group 4 Codes:

81479 UNLISTED MOLECULAR PATHOLOGY PROCEDURE

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph:

81225

Group 1 Codes:

ICD-10 Codes	Description
I20.0	Unstable angina
I20.1	Angina pectoris with documented spasm
I20.8	Other forms of angina pectoris
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
I21.29	ST elevation (STEMI) myocardial infarction involving other sites
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site
I21.4	Non-ST elevation (NSTEMI) myocardial infarction
I21.9	Acute myocardial infarction, unspecified
I21.A1	Myocardial infarction type 2
I21.A9	Other myocardial infarction type
I24.0	Acute coronary thrombosis not resulting in myocardial infarction
I24.1	Dressler's syndrome
I24.8	Other forms of acute ischemic heart disease
I24.9	Acute ischemic heart disease, unspecified
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm

ICD-10 Codes	Description
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris

Group 2 Paragraph:

81226

Group 2 Codes:

ICD-10 Codes	Description
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified
F31.31	Bipolar disorder, current episode depressed, mild
F31.32	Bipolar disorder, current episode depressed, moderate
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features
F31.60	Bipolar disorder, current episode mixed, unspecified
F31.61	Bipolar disorder, current episode mixed, mild
F31.62	Bipolar disorder, current episode mixed, moderate
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features
F31.75	Bipolar disorder, in partial remission, most recent episode depressed
F31.76	Bipolar disorder, in full remission, most recent episode depressed
F31.77	Bipolar disorder, in partial remission, most recent episode mixed
F31.78	Bipolar disorder, in full remission, most recent episode mixed
F31.9	Bipolar disorder, unspecified
F32.9	Major depressive disorder, single episode, unspecified
F33.0	Major depressive disorder, recurrent, mild
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms

ICD-10 Codes	Description
F33.40	Major depressive disorder, recurrent, in remission, unspecified
F33.41	Major depressive disorder, recurrent, in partial remission
F33.42	Major depressive disorder, recurrent, in full remission
F33.9	Major depressive disorder, recurrent, unspecified
G10	Huntington's disease

ICD-10 Codes that DO NOT Support Medical Necessity N/A
ICD-10 Additional Information Back to Top

General Information

Associated Information
N/A

Sources of Information
Ansell, J., Hirsh, J., & et al. (2008). The pharmacology and management of the vitamin K antagonists. The seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest*, 126(3), 204-233.

Berg, A.O., & et al. (2007). Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. *Genetics In Medicine*, 9(12), 819-825.

Berger, J.S., Bhatt, D.L., & et al. (2009). Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. *Circulation*, 120: 2337-2344.

Blake, C.M., Kharasch, E.D., & et al. (2013). Meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. *Clinical Pharmacology Therapeutics*, 94(3), 1-14.

Crews, K.R., Gaedigk, A., Dunnenberger, H.M., et al. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clinical Pharmacology Therapeutics*, 91(2): 321–326.

Dezentjé, V.O., Guchelaar, H.J., Nortier, J.W., van de Velde, C.J., & Gelderblom, H. (2009). Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. *Clinical Cancer Research*, 15(1):1521.

Flockhart, D. A., O'Kane, D., Williams, M.S., & et al. (2008). Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. *Genetics IN Medicine*, 10 (2), 139-150.

Gasche, Y. & Daali, Y. (2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *New England Journal of Medicine*, 351(27), 2827-2831.

Goetz, M.P., & Suman, V.J. (2013). DeYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. *Clinical Cancer Research*, 19(2), 500-507.

Gong, L., Thorn, C.F., Bertagnolli, M.M., Grosser, T., Altman, R.B., & Klein, T. E. (2012). Celecoxib pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenetics and Genomics*, 22(4), 310-318.

Herbild, L., Andersen, S.E., Werge, T., Rasmussen, H.B., & Jürgens, G. (2013). Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? *Basic & Clinical Pharmacology & Toxicology*, 113, 266-272.

Hicks, J.K., Swen, J.J., Thorn, C.F., & et al. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. *Clinical Pharmacology & Therapeutics*, 93(5), 402-408.

Johnson, J.A., Gong, L., & et al. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1genotypes and warfarin dosing. *Clinical Pharmacology & Therapeutics*, 90(4), 625-629.

Juel, J., Pareek, M., & et al. (2014). The clopidogrel-PPI interaction: An updated mini-review. *Current Vascular Pharmacology*. 12(5), 751-757.

Kawamura, M., Ohara, S., & et al. (2003). The effects of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. *Alimentary Pharmacology & Therapeutics*, 17, 965–973.

Klimkowicz-Mrowiec, A., Wolkowm, P., & et al. (2013). Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with Alzheimer's disease. *Neuropsychiatric Disease and Treatment*, 9, 1029-1033.

Lum, D.W.K., Perel, P., Hingorani, A.D., & Holmes, M.V. (2013). CYP2D6 Genotype and tamoxifen Response for Breast Cancer: A systematic review and meta-analysis. *PLoS One*, 8(10), e76648: PubMed Central PMCID: PMC3788742.

Matchar, D.B., Thakur, M.E., & et al. (2007). Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence report/technology assessment No. 146. (Prepared by the Duke evidence-based practice center under contract No. 290-02-0025) *AHRQ Publication* No. 07E002. Rockville, MD: Agency for Healthcare Research and Quality.

McClain, M.R., Palomaki, G.E., Piper, M., & Haddow, J.E. (2006). A rapid ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. *Genetics IN Medicine*, 10(2), 1-68.

Mega, J.L., Simon, T., & et al. (2010). Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. *Journal of the American Medical Association*, 304(16), 1821-1830.

Mehanna, R., Hunter C, & et al. (2013). Analysis of CYP2D6 genotype and response to tetrabenazine. *Movement Disorder*, 28 (2), 210-215.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Breast Cancer, Version 3.2015.

Rieder, M.J., Reiner, A.P., Gage, B.F., & et al. (2005). Effect of VKORC1haplotypes on transcriptional regulation and warfarin dose. *New England Journal of Medicine*, 352(22), 2285-2293.

Rodrigues, A.D. Commentary: IMPACT of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? *Drug Metabolism and Disposition*, 33(11), 1567-1575.

Samer, C.F., Lorenzini, K. Ing., V.Rollason., & et al. (2013). Applications of CYP450 testing in the clinical setting. *Molecular Diagnosis & Therapy*, 17:165-184.

Scott, S.A., Sangkuhl, K., Stein, C.M., & et al. (2013). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P4502C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update. *Clinical Pharmacology Therapeutic*, 94(3), 317-323.

Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., & et al. (2009). Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *Journal of the American Medical Association*, 302(8), 849-858.

Simon, T., Verstuyft, C., Mary-Krause, M., & et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. *New England Journal of Medicine*, 360(4), 363-375.

Tang, H.L., Li, Y., & et al. (2013). Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. *PLOS ONE*, 8(4).

Twardowschy, C.A., Werneck, L.C., & et al. (2013). The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy. *British Epilepsy Association*, 22, 194–197.

Villagra, D., Goethe, J., & et al. (2011). Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. *Biomarkers in Medicine*, 5(4), 427-438.

Visvanathan, K., Hurley, P., & et al. (2013). Update on the use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, 31(23), 2942-2962.

NA

Back to Top

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2017	R3	10/01/2017- ICD-10 code update: added I21.9, I21.A1 & I21.A9 to Group 1 Paragraph: 81225. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	• Revisions Due To ICD-10-CM Code Changes
07/01/2017	R2	07/01/2017-Added I25.111, I25.118, I25.119, I25.701, I25.708, I25.709, I25.711, I25.718, I25.719, I25.721, I25.728, I25.729, I25.731, I25.738, I25.739, I25.751, I25.758, I25.759, I25.761, I25.768, I25.769, I25.791, I25.798 and I25.799 to the list of covered codes for CPT code 81225 in Group 1.	• Other (Added ICD-010 Codes)
04/15/2017	R1	03/01/2017-Added 81479 to CPT/HCPC section Group 4- CYP gene panels (testing for more than 1 CYP gene on same date of service) is a single unit of service (UOS=1). All CYP panels should be billed with 81479 and are non-covered. Reworded CPT/HCPC Group 3 paragraph: CPT codes CYP2C9 and VKORC1 are non-covered for all indications per this policy. However, CYP2C9 and VKORC1 can be covered in accordance with NCD 90.1 and should be reported with HCPCS code G9143 warfarin responsiveness testing. Added MolDX to title & changed Contractor Determination number from Path-039 to to MolDX-002. Annual Review completed 02/02/2017.	• Other

Back to Top

Associated Documents

Attachments N/A

Related Local Coverage Documents Article(s) A55532 - MolDX: CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response Coding and Billing Guidelines A54921 - Response to Comments: Genetic Testing for CYP2C19, CYP2D6, CYP2C9, and VKORC1 (L36398). LCD(s) DL36398 - (MCD Archive Site)

Related National Coverage Documents NCD(s) 90.1 - Pharmacogenomic Testing for Warfarin Response

Public Version(s) Updated on 09/20/2017 with effective dates 10/01/2017 - N/A Updated on 06/20/2017 with effective dates 07/01/2017 - 09/30/2017 Updated on 03/02/2017 with effective dates 04/15/2017 - 06/30/2017 Updated on 02/17/2016 with effective dates 04/16/2016 - N/A Back to Top

Keywords

N/A Read the **LCD Disclaimer** Back to Top